| |
TetraQ is rapidly growing and expanding its services to clients. Please check out this website for the latest additions and news at TetraQ, or subscribe to our mailing list by emailing
Rose-marie Pennisi at r.pennisi@tetraq.com.au.
Latest News & Announcements:
Bright spark boosts TetraQ’s services
15th March 2010 BRISBANE-based preclinical contract research organisation TetraQ is set to almost double its throughput for analysis of samples for the pharmaceutical and biotech industry with the implementation of a leading edge technology system. TetraQ, based at The University of Queensland, commissioned its $300,000 Spark Symbiosis direct on-line solid-phase extraction sample preparation system from The Netherlands late last year. The innovation has already received positive feedback from clients. TetraQ Bioanalysis facility manager Dr Russell Addison said the robotic sample preparation equipment allowed the contract research organisation to process samples from clinical trials and preclinical trials more efficiently. ``The Spark robotics, linked to our triple quadrupole mass spectrometers and validated WinNonLin data processing software, provides significant advantages to our clients in the pharmaceutical industry to whom time is of the essence’’ Dr Addison said. ``The Symbiosis system is an automated on-line sample preparation system that uses separate solid phase extraction cartridges to extract the drugs being tested from plasma. ``The direct analysis of plasma samples to speed up sample analysis has always been our goal. ``This machine greatly assists with the throughput of this analysis, so it can contribute to decreasing the overall time required to get a new drug or a new formulation onto the market. ``We are experiencing at least a 30 per cent reduction in project time from commencement of analysis to the final report to our customers. ``The Spark decreases the requirement for the use of large volumes of organic solvents usually used in the more traditional manual-extraction procedure. This has cost and environmental advantages as well,’’ he said. Dr Keith Dredge, Preclinical Development director of TetraQ client Progen Pharmaceuticals Limited, said the Spark Symbiosis System had enabled TetraQ to develop a fully validated bioanalytical assay for our lead drug candidate, which was proving extremely difficult with conventional methods and instrumentation. “Apart from keeping our drug development project on track, we are confident that this instrument, together with TetraQ's expertise, will support the evolutionary changes that typically arise during the drug development process as we move our product into the clinic”, Dr Dredge said. TetraQ is the first preclinical contract research organisation in Australia to be equipped with this leading edge technology that provides services to biopharmaceutical industry clients locally and internationally to assist them with their development of a broad range of drug and biological products. TetraQ - Finalist for the inaugural UQ Safety Award
The Centre for Integrated Preclinical Drug Development (CIPDD)/TetraQ has made significant advances in preventative safety management practice. Our record in this area has been achieved through the use of world recognised quality systems. Safety training alone will not achieve sustainable outcomes. Our staff receive regular safety and technical training so that tasks are performed right first time with the dual focus of excellence in technical performance and safety.
CIPDD/TetraQ has achieved worldwide accreditation for ISO 17025 (R&D) and Good Laboratory Practice (GLP) through the National Association of Testing Authorities. Our system of:
-
Corrective and Preventive Actions
-
Documented induction and annual refresher training
-
Root cause analysis
-
Standard Operating Procedures (SOPs)
-
Training records
-
Internal audits
-
Audits by compliance authorities (NATA)
-
Risk Assessments
ensures a high awareness of safety and a rapid and sustainable response to safety incidents. Our teams participate in the solution to an issue, one that must not only correct the issue but provide a long term sustainable preventive outcome as well. Importantly, the outcomes are documented and followed up by our full time Quality Assurance Manager. This system of staff participation and independent checks and balance assures an optimal and sustainable outcome and a significant reduction in risk
TetraQ expands into lucrative Japanese pharmaceutical market
Brisbane, QLD, Australia, 26 October 2009 – Two of Australia’s leading contract research organisations, TetraQ and Q-Pharm Pty Ltd, have announced a collaboration with Japanese clinical trial organisation, MORE Medical, in a step to promote Queensland’s high quality drug development capabilities, particularly in preclinical drug development and early phase clinical trials.
TetraQ, the commercial arm of The University of Queensland’s (UQ), Centre for Integrated Preclinical Drug Development, believes establishing itself in Japan will help promote the benefits of outsourcing clinical and preclinical research and development to Queensland.
CEO Professor Maree Smith said the collaboration was years in the making and might not have been possible without the strong support of UQ spin out partner Q-Pharm, the Queensland Clinical Trials Network (QCTN) and the Queensland State Government.
“Over the last three to four years we have been working together in promoting Queensland’s high quality preclinical and clinical trial capabilities in Japan,” she said.
“At TetraQ we sit in the translational research space; we assist universities, small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the market.”
“We perform preclinical trials, to evaluate these drugs for their efficacy, to assess whether or not they do what the company thinks they do, and for their safety to ensure they are sufficiently safe to go on to be tested in early stage human clinical trials.”
Professor Smith said the collaboration would be a win for all parties involved.
“It is a great opportunity for TetraQ and Q-Pharm to establish a significant presence within Japan, which is encouraging the ‘outsourcing model’. This model is used very effectively by both U.S. pharmaceutical companies as well as biotechnology companies in Australia, the U.S. and elsewhere to control costs of new drug development.”
“It allows MORE Medical to grow their business in a competitive Japanese market, through the collaboration with TetraQ’s preclinical capabilities and Q-Pharm’s specialist Phase I and II clinical trials.”
“It is also a success for the Queensland Government and UQ, which has invested millions into TetraQ.”
Q-Pharm CEO, Mr Terry Hurst, said the company offered significant advantages to Japanese clients in terms of cost, quality and efficiency in conducting early phase clinical trials. “As a well established and globally focussed business, Q-Pharm has an excellent track record in overseas markets and is well positioned to service the Japanese clinical trial sector, particularly in the area of Japanese-Caucasian bridging studies”.
This announcement was made by The Queensland Trade Commissioner for Japan, Mr Tak Adachi at a Global Engaging Event held in Brisbane last Friday, 23rd Oct 2009.
Mr Adachi and the Queensland Minister for Trade, Mr Stephen Robertson, were credited for their work in support of the collaboration.
TetraQ Conducts its first Adelaide Seminar
TetraQ together with co-sponsors Nucleus Network, BioInnovationSA, Centre for Innovation SA and Pharmaceutical Packaging Professionals conducted the first Adelaide seminar as part of its national preclinical seminar series. This was a successful event presented by Professor Evan Siegel of Ground Zero Pharmaceutics, CA. This was the first in the Adelaide series, the topic covered was "Getting to the IND". Following very positive feedback we will return with advanced subject matter for 2010.
Preclinical CRO, TetraQ Appoints K. Dyszynski to North America BD Position
10th September 2009
Brisbane, QLD, Australia, 10 September 2009 – TetraQ, the commercial arm of The University of Queensland’s Centre for Integrated Preclinical Drug Development (CIPDD), has appointed Kris Dyszynski to the position of Business Development, North America.
As one of Australia’s leading preclinical contract research organisations (CRO’s), TetraQ (a registered business of UniQuest Pty Ltd) believes establishing a North American based development officer will help forge new business relationships and opportunities.
TetraQ CEO Maree Smith said the Queensland Smart State Entrepreneur-In- Residence Grant, worth $225,000 and announced recently by Treasurer Andrew Fraser, made the appointment possible.
“Mr Dyszynski’s new role will be undertaking business development activities for TetraQ within North America and identifying collaborative research and development activities for the CIPDD.”
“At TetraQ we sit in the translational research space; we assist universities, small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the market,” she said.
“We perform preclinical drug trials, showing these drugs are efficacious – they do what the company says they do – and that they’re safe to go on to human trials.”
“This is a great opportunity for TetraQ and the CIPDD to establish a tangible presence within North America that further builds on TetraQ’s existing international reach and activities.”
Mr. Dyszynski has over 25 years of business experience in the biotechnology industry, with global responsibilities.
Prior to joining TetraQ, Mr. Dyszynski was based in the US as Vice President, Business Development for Australian company Alchemia Limited.
Mr Dyszynski said his new role gave TetraQ someone on the ground in North America, which enjoyed a significant proportion of the global R & D spend on preclinical development – worth almost $4 billion in 2008.
“There’s no real Australian Preclinical Contract Research Organisation (CRO) footprint in North America at present,” he said, “which means TetraQ can really make an impact.”
“TetraQ is at a distinct advantage in that it can offer an attractive value proposition for clients in North America by providing a high quality, good value, personalised service which is tailored to meet their specific needs.”
“So we have the opportunity here to bring a lot of preclinical drug development business into Australia.”
TetraQ expects the appointment will also facilitate knowledge diffusion between Mr. Dyszynski, who’s located in the US, and TetraQ and its other University of Queensland stakeholders, with further opportunities arising during his regular visits to Australia.
TetraQ Conducts 2nd Melbourne and 1st Sydney Seminar Workshop
25th June 2009
TetraQ with co-sponsors Nucleus Network and Pharmaceutical Packaging Professionals conducted their 2nd seminar in Melbourne. This was sucessful with a number of delegates returning from the previous year. This years topic was "CMC & ADME Strategies for Preclinical Development of Drugs" as conducted in Brisbane earlier this year. We thank BioMelbourne who supported this event by promoting it to their members.
Together with co-sponsors Clinical Trial NSW, Nucleus Network and Pharmaceutical Packaging Professionals, TetraQ conducted its first Sydney seminar / workshop "Getting to the IND". This event was supported by the University of Technology, Sydney, who kindly provided an ideal venue and assited with prepArations for the event. Delegates who attended provided very positive feedback and have convinced us that we should return with a new and exciting topic for next year
TetraQ Conducts Brisbane Workshop, First in 2009 Series
11th March 2009
TetraQ with sponsor partners Q-Pharm and QCTN conducted their first seminar in the 2009 National Preclinical Drug Development Seminar Series in Brisbane. CMC & ADME Strategies for Preclinical Development of Drugs and Biologics. Presented by Dr Evan Siegel, adjunct professor of UQ, CEO & president of Ground Zero Pharmaceuitcs based in Irvine California, USA. Numbers were up from the previous year including several interstate and international delegates which is very encouraging given the present economic climate. Overall feedback indicates that this is relevant and engaging specialist education that meets the needs of Australian biotechnology.
Chemical Safety Seminar - TetraQ & CIPDD UQ
20th February 2009
TetraQ with sponsors, (CIPDD) Centre for Intgrated Preclinical Drug Development and (UQ) The University of Queensland conducted the first seminar in a series that wil focus on regulatory matters in chemical safety. Speaker, Drs. Henk van Peski is an adjunct professor at UQ and principle consultant with Chemwatch, Henk also in chief editor of Chemiezone. Henk is base in The netherlands and is a leading authority in regulatory affairs of REACH.
DNDI Seminar - TetraQ & CIPDD & UQ
27th January 2009
TetraQ supported by sponsors CIPDD and The University of Queensland (UQ) presented a 2 part seminar with speaker, Dr Rob Don. Rob is an adjunct professor of UQ and is Senior program Director for DNDI, Drugs for Neglected Dieases Initiative based in Geneva, Switzeralnd. The topics of Robs seminar were: Global Public Health Policy & Drug Delivery of High Quality Medicines for Neglected Diseases in Developing Countries. And: Opportunities and Strategies for Australian Researchers in Drug Discovery Aimed ar Delivering New Medicines for Neglected Diseases.
TetraQ Confirms National Seminar Series for 2009
12 January 2009
TetraQ has confirmed that they will conduct 4 National Preclinical Drug Development Seminar/Workshops through 2009. Starting in Brisbane 11th March 2009 with focus to CMC & ADME Strategies for preclinical Development of Drugs and Biologics.
National Preclinical Drug Development Seminar Series dates for 2009
Due to ongoing success and strong demand we are now conducting the drug development series nationally
Brisbane: 11th March 09
Melbourne: 16th June 09
Sydney: 18th June 09
Adelaide: 22nd October 09
Event feedback...
...Directly relevant to preclinical & drug development
...Excellent case studies
...Raised good questions for discussion
11th March 2009 - BRISBANE - CMC & ADME Strategies for preclinical Development of Drugs and Biologics will be conducted by Prof Evan Siegel, President & CEO of Ground Zero Pharmaceuticals, California, USA.
Prof Siegel has considerable experience with the US FDA and consulting on preclinical drug development to Pharmaceutical, Biologics, Biotechnology and Medical Device firms worldwide.
Prof Evan Siegel's presentation will include an overview of current drug and biologics development, concentrating on:
CMC Development
Preclinical/nonclinical ADME
Effective FDA Strategies
Brisbane Event Co-sponsors: Q-Pharm & (QCTN) Queensland Clinical Trials Network
Seminar & Workshop Overview
Appropriate drug and biologic development must involve an integrated approach to the key disciplines that determine product quality, safety and marketability as early in the process as possible.
Chemistry, manufacturing and controls considerations begin at the preclinical stage and continue through approval of a medical product.
This full-day seminar will cover technical issues and effective FDA strategies that can reduce financial expenditures in early development; preserve scarce resources; and maximize the impact of intellectual capital on the progress of product development and investor confidence.
Formal presentations on CMC and ADME will each be followed by an extensive case study that illustrates the application of the principles covered in the “real world.”
Time for Questions and Answers will be provided including excellent opportunities for networking.
TetraQ and Q-Pharm co-exhibiting at AusBiotech08
26-29 October 2008
TetraQ and Q-Pharm co-exhibited at AusBiotech08, one of our industries most important events. This event was held at the Melbourne Convention Centre. This was a very well attended event where the nations most prominent biotech organisations were present. The general feeling at this event was very positive, irrespective of external events throwing financial institutions into chaos. The reason it is believed that there is a positive future for Australian biotech is due to our maturing industry, with our solid skills base in expertise and the great value that Australian exporters/service providers represent to international clients.
TetraQ CEO Professor Maree Smith recieves WiT's top award
27 September 2008
The Women in Technology awards focus on recognizing the achievements of women working in the information technology and biotechnology industries. TetraQ CEO, Professor Maree Smith has received WiT’s, The Outstanding Achievement Award which is the highest honor for the Biotech Chapter of WiT - with the winner becoming WiT Ambassador for the ensuing 12 months.
Professor Maree Smith has a broad range of expertise in preclinical and clinical drug development, including animal models of human disease, assay development, validation and in vivo pharmacokinetics in animals and humans. Maree is one of Australia’s leading researchers in the pain field and has particular expertise in testing effectiveness of molecules as pain drugs. Maree has considerable experience in commercialization of intellectual property which makes her well placed to understand the early stage needs of biopharmaceutical companies.
WiT, President - Anne-Marie Birkill says, “Maree is such a wonderful role model and a truly delightful (and modest) person, too”. As WiT Biotech Ambassador we will be asking Maree to speak at and attend various WiT engagements during the course of the year and to engage in dialogue e.g. in our newsletters and other publications. We will promote Maree as a role model and in turn ask Maree to promote WiT and other successful women working in the biotechnology industry.
TetraQ & Q-Pharm co-presented at BioCareers08
9 September 2008
BioCareers is an event to bring together over 250 tertiary students to meet with representatives from the pharmaceutical and biotechnology industries to discuss careers in the field, and to establish important contacts for the future. The evening involves the opportunity to network, recruit and educate attendees in regard to career paths in these industries. TetraQ & Q-Pharm representatives were on hand to offer advice and guidance as needed.
Preclinical Seminar Series Registration
14 August 2008
The First Melbourne Preclinical Drug Development Workshop to be hosted by Professor Evan Siegel, President & CEO of Ground Zero Pharmaceuticals, California, USA.
Event Co-sponsor: Nucleus Network.
Preclinical Drug Development Seminar Series Thursday14th August 2008
13 May 2008
Successful launch of the Preclinical Drug Development Seminar Series "Getting to the IND"
This event was well attended by 50 delegates who came from proffessional and academic segments of the Australian biopharmaceutic industry.
Strategic Alliance between TetraQ and Q-Pharm
13 June 2008
TetraQ, the integrated preclinical contract research provider based at The University of Queensland (UQ), and Q-Pharm, a leading early phase clinical trial facility in Australasia, have formed a strategic alliance to enhance the delivery of bioanalytical services to clients in the biotechnology and pharmaceutical industries.
The alliance is considered to be a positive development for the two businesses, which are both commercialization enterprises of the University facilitating industry access to UQ’s cutting-edge research resources and expertise.
TetraQ is a leading contract research organization that offers a broad range of preclinical services to the biopharmaceutical industry. A component of TetraQ’s services includes bioanalytical services supporting clinical studies (including bioavailability/ bioequivalence and drug-drug interaction studies).
Q-Pharm is a Phase 1 clinical trial provider, servicing the early phase trial requirements of the pharmaceutical and biotech industries in Australia and around the world.
According to Q-Pharm CEO, Professor Wayne Hooper, the alignment of the two organizations at the interface of the preclinical and early phase clinical stages of the drug development pathway presents significant opportunities for capturing operational economies, co-marketing of services and cross-referral of potential clients.
“Since 2002 Q-Pharm has been one of Australia’s foremost providers of bioanalytical services in support of clinical studies. When we decided to outsource our bioanalytical services to TetraQ the synergistic possibilities became more apparent,” Professor Hooper said.
“We can expand our range of services to existing and future clients with TetraQ’s involvement. It’s a very positive step forward for both businesses as well as our clients.”
TetraQ’s Executive Director, Professor Maree Smith, also recognized the advantages of a strategic alliance.
“TetraQ has a strong track record in fully-validated bioanalytical method development and sample analysis and we are recognized leaders in this area,” Professor Smith said.
“TetraQ’s GLP recognition and NATA ISO 17025 (R&D) accreditation has positioned TetraQ as the leading integrated preclinical service provider to the Australian biopharmaceutical industry. Q-Pharm is an industry leader in Phase 1 clinical trials so the alliance offers a consistent and reliable level of service”.
The alliance was negotiated with the support of UniQuest Pty Limited, UQ’s main commercialisation company. UniQuest was also responsible for setting up TetraQ as the commercial arm of the Centre for Integrated Preclinical Drug Development at UQ and Q-Pharm as a joint venture with the Queensland Institute of Medical Research.
With their world-recognized credentials, both TetraQ and Q-Pharm have established enviable reputations for high quality services. Both organizations are committed to operating within quality frameworks that comply with the relevant industry-related international standards.
TetraQ was established in 2005 as the first contract research organization in Australia to provide integrated preclinical services to the global pharmaceutical and biotechnology industries. Its state-of-the-art facilities and equipment meet stringent quality and testing standards, and its bioanalytical work is accepted internationally for regulatory review, providing clients in the pharmaceutical and biotechnology industries with a high degree of assurance.
Emerging from UQ’s Centre for Studies in Drug Disposition, Q-Pharm Pty Limited has grown rapidly in the past six years to become a major provider of Phase 1 clinical trial services to national and international clients. It also conducts Phase I clinical trials, pharmacokinetic studies and bioequivalence studies from its state-of-the-art facilities within the Royal Brisbane and Women’s Hospital.
Tetra Q achieves GLP recognition for Toxicology Services
22 October 2007
TetraQ, the integrated preclinical contract research provider based at The University of Queensland (UQ), has attained Good Laboratory Practice (GLP) recognition for its toxicology services after satisfying rigorous internationally-benchmarked criteria.
The additional accreditation from the National Association of Testing Authorities (NATA) for another of its key laboratories means that as well as GLP bioanalytical services, TetraQ can provide local and international clients with GLP compliant toxicology services including genotoxicity, dose range-finding, acute and repeat-dose studies.
TetraQ’s Executive Director, Professor Maree Smith, said the GLP accreditation for its toxicology and ADME laboratories has now positioned TetraQ as the leading integrated preclinical service provider to the Australian biopharmaceutical industry.
“TetraQ’s decision to offer toxicology services, including toxicokinetics, allows us to leverage our strong track record in fully-validated bioanalytical method development and sample analysis,” Professor Smith said.
“We are delighted to be able to offer our clients in Australia and overseas an extended, internationally accredited service delivery which includes acute and chronic toxicology services,” said Professor Smith.
Toxicology services include cytotoxicity assays, genotoxicity assays - bacterial mutation (Ames) tests; mouse lymphoma assay; mammalian erythrocyte micronucleus testing; dose range finding; safety pharmacology (cardiovascular, central nervous and respiratory systems); off-target screening; and hERG binding assays.
TetraQ has state-of-the-art facilities and equipment which meet stringent quality and testing standards to conduct toxicology studies that can be recognized by international regulatory authorities.
“GLP recognition is required for regulatory submissions on later-stage toxicology studies, and because we have designed our early-stage services to generate data that will provide valuable input into the planning of more expensive and extensive GLP regulatory studies, we can offer clients a stream-lined suite of screening services. We can also interpret and provide advice on toxicology reports our clients have received from other contract research organisations,” Professor Smith said.
TetraQ was established in 2005 as the first contract research organisation in Australia to provide integrated preclinical services to the global pharmaceutical and biotechnology industries. It is the commercial arm of the Centre for Integrated Preclinical Drug Development at UQ and a registered business of UniQuest Pty Ltd, the main commercialisation company of The University of Queensland.
TetraQ receives funding for $1.73M project from Qld Government
11 April 06
TetraQ is very pleased to announce that it has received funding for a collaborative project to develop new tools for preclinical drug development. The project involves contribution by three industry partners and a grant of $865,000 from the Qld Government's Research-Industry Partnership Program to the Centre for Integrated Preclinical Drug Development at the University of Queensland . This will allow the Centre to develop new preclinical tests that will be available from TetraQ in the future.
To read the press release, click here:
Research-Industry Partnership Program Grant Media Release
TetraQ Roadmap of Drug Development Launched
3 April 2006
In response to client requests, we have developed the TetraQ Roadmap of Drug Development, an interactive tool which will be permanently available on the "services overview" page of our website (click here). It was designed to assist companies developing drugs in the preclinical stage to understand the range of choices of preclinical testing, and also to clearly show how TetraQ offers an integrated solution. It is the result of consultation with experts in the industry and from client feedback.
To view and download the Roadmap, click here:
TetraQ Roadmap.pdf
International approval for Australian pharmaceutical testing
10 July 2007
University of Queensland (UQ) based contract research organisation, TetraQ, is now recognised to provide internationally accredited testing services to the Australian biopharmaceutical industry.
TetraQ, an integrated preclinical drug development service provider, has attained official Good Laboratory Practice (GLP) recognition from the National Association of Testing Authorities (NATA) for one of its key laboratories.
To read the press release, click here: GLP.pdf
Refurbishment of TetraQ's toxicology laboratory completed
Along with the completion of the Pharmaceutics laboratory in late 2005, TetraQ's toxicology laboratory has now been refurbished to be a state of the art facility for the conduct of toxicology testing and research. Refurbishment of the toxicology animal holding facility is ongoing. Also, the complete refurbishment of the efficacy laboratory is expected to be complete by the end of April 2006 whilst the ADME laboratory refurbishment is about to commence. In total, $4M will be spent on these refurbishments, with a further $4M to be spent on equipment. These funds have been provided by the Queensland Government's Smart State Research Facilities Fund.
Parkinson's and Alzheimer's models now available
TetraQ now offers a validated model of Parkinson's disease. Click here for more information:
Parkinson's Model
We also now offer a validated model of Alzheimer's Disease. Click here for more information:
Alzheimer's Model
Alchemia and TetraQ collaborate on new pain treatments
2 December 2005
TetraQ is pleased to announce that it will collaborate with Alchemia to assist its development of new pain drugs. TetraQ will work on developing new in vitro assays to screen compounds generated from Alchemia's VAST platform. The collaboration is supported by a $372,000 ARC linkage grant awarded to UQ's Centre for Integrated Preclinical Drug Development and will enable TetraQ to offer novel in vitro pain models in the future.
To read the the media statement released on 2 December 2005, click here:
Alchemia-TetraQ Collaboration.pdf
TetraQ forms partnership with Ground Zero Pharmaceuticals
18 November 2005
TetraQ is pleased to announce a partnership with Ground Zero Pharmaceuticals (GZP), a regulatory affairs and product development consulting firm based in Irvine, Southern California. GZP brings a wealth of experience and expertise in issues related to early stage drug development and seeking regulatory approval for new drugs, particularly with the FDA in the USA.
To read the media statement, click here:
Strategic plan to accelerate Australian drug development
TetraQ ADME laboratory receives NATA R&D accreditation
20 December 2005
Australia's first Research and Development (R&D) Accreditation has been granted to TetraQ - ADME by the National Association of Testing Authorities (NATA).The R&D accreditation is a new program developed by NATA and TetraQ- ADME has worked closely with NATA over the past several years, culminating in the awarding of Australia's first R&D accreditation on the 10th of August, 2005
The scope of accreditation includes "management and conduct of research into pharmaceutical /biotechnology agents using appropriately validated human and mammalian animal models applicable to adsorption/distribution/metabolism/elimination studies and involving the determination of analytes in biological matrices." (source: NATA website, www.nata.asn.au, search for TetraQ).
The lab was first accredited by NATA in 1997 in the program of medical testing and for the application of the principles of OECD prinicples of Good Laboratory Practice (GLP), when it was known as the Centre for Studies in Drug Disposition (CSDD). It was recognized as being competent to produce valid laboratory data in accordance with ISO Guide 25, and later, its successor ISO/IEC Guide 17025 - 1999.
In addition to NATA R&D accreditation, TetraQ-ADME plans to seek the OECD GLP accreditation in 2006. TetraQ will also seek OECD GLP recognition and R&D accreditation for its Toxicology laboratory, as well as R&D accreditation for its Efficacy and Pharmaceutics laboratories in 2006.
To read a recent article on TetraQ in NATA News, click here: NATANews_TetraQ_Article.pdf
Pharmaceutics laboratory refurbishment complete
20 December 2005
Utilising funding provided by an $8.1M grant from the Queensland Government's Smart State Research Facilities Fund, TetraQ is refurbishing over 1000 square metres of laboratory space, and installing $4M dollars worth of new, state of the art equipment.
We have recently completed refurbishment of the TetraQ Pharmaceutics laboratory, and are currently installing specialised equipment to facilitate the physicochemical characterisation and preclinical formulation of new pharmaceuticals amongst other pharmaceutics services. Refurbishment of the three other TetraQ laboratories is on track, and due for completion in early-mid 2006.
|
